Article
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2015
Cooper Wendy A, Tran Thang, Vilain Ricardo E, Madore Jason, Selinger Christina I, Kohonen-Corish Maija, Yip PoYee, Yu Bing, O'Toole Sandra A, McCaughan Brian C, Yearley Jennifer H, Horvath Lisa G, Kao Steven, Boyer Michael, Scolyer Richard A
Abstract excerpt
OBJECTIVES: Immune checkpoint blockade using inhibitors of programmed death-1 have shown promise in early phase clinical trials in NSCLC and programmed death-ligand 1 (PD-L1) tumoral expression could potentially be a useful predictive marker. Data reporting the prevalence of PD-L1 expression in NSCLC and clinicopathologic associations is very limited. We sought to determine the frequency of PD-L1 expression in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
